36
Participants
Start Date
May 14, 2025
Primary Completion Date
December 2, 2027
Study Completion Date
June 8, 2028
TAK-411
TAK-411 IV infusion.
NOT_YET_RECRUITING
Icahn School of Medicine at Mount Sinai, New York
NOT_YET_RECRUITING
Hospital of The University of Pennsylvania, Philadelphia
NOT_YET_RECRUITING
Emory University, Atlanta
NOT_YET_RECRUITING
UF Health Neurology - Jacksonville, Jacksonville
RECRUITING
Visionary Investigators Network, Miami
NOT_YET_RECRUITING
University of South Florida, Tampa
NOT_YET_RECRUITING
Neuro ClinicaS.A.S, Medellín
NOT_YET_RECRUITING
Mayo Clinic Rochester, Rochester
NOT_YET_RECRUITING
The Washington University, St Louis
NOT_YET_RECRUITING
The Curators of the University of Missouri on behalf of University of Missouri Health Care, Columbia
NOT_YET_RECRUITING
Ochsner Clinic Foundation, New Orleans
NOT_YET_RECRUITING
Houston Methodist Research Institute, Houston
NOT_YET_RECRUITING
California Pacific Medical Center, San Francisco
NOT_YET_RECRUITING
University of Washington, Seattle
NOT_YET_RECRUITING
ClinicaReina Sofia, Bogotá
NOT_YET_RECRUITING
FundacionOftalmologicade Santander FOSCAL, Floridablanca
NOT_YET_RECRUITING
Fundacion Valle del Lili, Santiago de Cali
RECRUITING
University of California San Diego, La Jolla
NOT_YET_RECRUITING
Beth Israel Deaconess Medical Center, Boston
NOT_YET_RECRUITING
University of Calgary, Calgary
NOT_YET_RECRUITING
University Health Network, Toronto
NOT_YET_RECRUITING
Hospital Universitario San Ignacio, Bogotá
Lead Sponsor
Takeda
INDUSTRY